Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

详细信息    查看全文

• 作者：Debra M Meyer (1)
  Michael I Jesson (1)
  Xiong Li (1)
  Mollisa M Elrick (2)
  Christie L Funckes-Shippy (1)
  James D Warner (1)
  Cindy J Gross (2)
  Martin E Dowty (3)
  Shashi K Ramaiah (2)
  Jeffrey L Hirsch (1)
  Matthew J Saabye (1)
  Jennifer L Barks (1)
  Nandini Kishore (1)
  Dale L Morris (2)
  
• 刊名：Journal of Inflammation
• 出版年：2010
• 出版时间：December 2010
• 年：2010
• 卷：7
• 期：1
• 全文大小：821KB
• 参考文献：1. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Brissette WH, McCurdy SP, Kudlacz EM, Conklyn MJ, Elliott EA, Koslov ER, Fisher MB, Strelevitz TJ, Yoon K, Whipple DA, Sun J, Munchhof MJ, Doty JL, Casavant JM, Blumenkopf TA, Hines M, Brown MF, Lillie BM, Subramanyam C, Shang-Poa C, Milici AJ, Beckius GE, Moyer JD, Su C, Woodworth TG, Gaweco AS, Beals CR, Littman BH, Fisher DA, Smith JF, Zagouras P, Magna HA, Saltarelli MJ, Johnson KS, Nelms LF, Des Etages SG, Hayes LS, Kawabata TT, Finco-Kent D, Baker DL, Larson M, Si M-S, Paniagua R, Higgins J, Holm B, Reitz B, Zhou Y-J, Morris RE, O'Shea JJ, Borie DC: Prevention of organ allograft rejection by a specific janus kinase 3 inhibitor. / Science 2003, 302: 875鈥?78. CrossRef
  2. Borie DC, O'Shea JJ, Changelian PS: Jak3 inhibition, a viable new modality of immunosuppression for solid organ transplants. / Trends Mol Med 2004, 10: 532鈥?41. j.molmed.2004.09.007">CrossRef
  3. Ortmann RA, Cheng T, Visconti R, Frucht DM, O'Shea JJ: Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development, and immunoregulation. / Arthritis Res 2000, 2: 16鈥?2. CrossRef
  4. Kudlacz E, Perry B, Sawyer P, Conklyn M, McCurdy S, Brissette W, Flanagan M, Changelian P: The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. / Am J Transplant 2004, 4: 51鈥?7. j.1600-6143.2003.00281.x">CrossRef
  5. O'Shea JJ, Pesu M, Borie DC, Changelian P: A new modality for immunosuppression: Targeting the JAK/STAT pathway. / Nat Rev Drug Discov 2004, 3: 555鈥?64. CrossRef
  6. Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O'Shea JJ: Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. / Immunol Rev 2005, 203: 127鈥?42. j.0105-2896.2005.00220.x">CrossRef
  7. Gupta P, Friberg LE, Karlsson MO, French JL, Krishnaswami S: Semi-mechanistic modeling of the effect of CP-690,550 on circulating neutrophils in patients with rheumatoid arthritis (RA) [abstract]. / Clin Pharmacol Ther 2009, 85: S7. j.clpt.2008.282">CrossRef
  8. Gupta P, Friberg LE, Karlsson MO, Krishnaswami S, French J: A semi-mechanistic model of drug-induced reduction in neutrophil counts in patients with rheumatoid arthritis. / J Clin Pharmacol 2010, 50: 679鈥?7. CrossRef
  9. Boy MG, Wang C, Wilkinson BE, Chow VF-S, Clucas AT, Krueger JG, Gaweco AS, Zwillich SH, Changelian PS, Chan G: Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. / J Invest Dermatol 2009, 129: 2299鈥?302. jid.2009.25">CrossRef
  10. van Gurp E, Weimer W, Gaston R, Brennan D, Mendez R, Pirsch J, Swan S, Pescovitz MD, Ni G, Wang C, Krishnaswami S, Chow V, Chan G: Phase 1 dose-escalation study of CP-690,550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. / Am J Transplant 2008, 8: 1711鈥?718. j.1600-6143.2008.02307.x">CrossRef
  11. Lawendy N, Krishnaswami S, Wang R, Gruben D, Cannon C, Swan S, Chan G: Effect of CP-690,550, an orally active Janus kinase inhibitor, on renal function in healthy adult volunteers. / J Clin Pharmacol 2009, 49: 423鈥?29. CrossRef
  12. Ohtsu S, Yagi H, Nakamura M, Ishii T, Kayaba S, Soga H, Gotoh T, Rikimaru A, Kokubun S, Itoh T: Enhanced neutrophilic granulopoiesis in rheumatoid arthritis. Involvement of neutrophils in disease progression. / J Rheumatol 2000, 27: 1341鈥?1.
  13. Silverfield J, Connel C, Bloom B, Gruben D, Kanik K, Poiley J, Polak P, Burson JS, Tate G, Wallenstein G, Wilkinson B, Zwillich S: CP-690,550, an oral JAK inhibitor, is a well-tolerated and effective long-term treatment for patients with moderate to severe rheumatoid arthritis [abstract]. / American College of Rheumatology Scientific Meeting Proceedings 2008., 716:
  14. Paraganas E, Wang D, Stravopodis D, Topham DJ, Marine J-C, Teglund S, Vanin EF, Bodner S, Colamonici OR, van Deursen JM, Grosveld G, Ihle JN: Jak2 is essential for signaling through a variety of cytokine receptors. / Cell 1998, 93: 385鈥?95. CrossRef
  15. Brizzi MF, Aronica MG, Rosso A, Bagnara GP, Yarden Y, Pegoraro L: Granulocyte-macrophage colony-stimulating factor stimulates Jak2 signaling pathway and rapidly activates p93 ^fes , Stat1 p91, and Stat3 p92 in polymorphonuclear leukocytes. / J Biol Chem 1996, 271: 3562鈥?567. jbc.271.7.3562">CrossRef
  16. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K: Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. / Cell 1998, 93: 397鈥?09. CrossRef
  17. Milici A, Kudlacz EM, Audoly L, Zwillich S, Changelian P: Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. / Arthritis Res Ther 2008, 10: 1鈥?. CrossRef
  18. Segel IH: Simple inhibition systems. In / Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. John Wiley & Sons, Inc., New York; 1993:100鈥?60.
  19. Pereira C, Clarke E, Damen J: Hematopoietic colony-forming cell assays. / Methods Mol Biol 2007, 407: 177鈥?08. CrossRef
  20. Criswell KA, Bleavins MR, Zielinski D, Zandee JC, Walsh KM: Flow cytometric evaluation of bone marrow differentials in rats with pharmacologically induced hematologic abnormalities. / Cytometry 1998, 32: 18鈥?7. CrossRef
  21. Conklyn M, Andresen C, Changelian P, Kudlacz E: The Jak3 inhibitor CP-690,550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing. / J Leukoc Biol 2004, 76: 1248鈥?255. jlb.0504282">CrossRef
  22. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP: A quantitative analysis of kinase inhibitor selectivity. / Nat Biotechnol 2008, 26: 127鈥?32. CrossRef
  23. Ghoreschi K, Laurence A, O'Shea JJ: Selectivity and therapeutic inhibition of kinases: to be or not to be? / Nat Immunol 2009, 10: 356鈥?60. CrossRef
  24. Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, King KL, Sheehan KCF, Yin L, Pennica D, Johnson EM Jr, Schreiber RD: Disruption of the Jak1 gene demonstrates obligatory and non-redundant roles of the Jaks in cytokine-induced biologic responses. / Cell 1998, 98: 373鈥?83. CrossRef
  25. Rui L, Carter-Su C: Identification of SH2B尾 as a potent cytoplasmic activator of the tyrosine kinase Janus kinase 2. / Proc Natl Acad Sci USA 1999, 96: 7172鈥?177. CrossRef
  26. Ward PA: Neutrophils and adjuvant arthritis. / Clin Exp Immunol 1997, 107: 225鈥?26. j.1365-2249.1997.00276.x">CrossRef
  27. Miossec P: IL-17 and Th17 cells in human inflammatory diseases. / Microbes Infect 2009, 11: 625鈥?30. j.micinf.2009.04.003">CrossRef
  28. Ottonello L, Cutolo M, Frumento G, Arduino N, Bertolotto M, Mancini M, Sottofattori E, Dallegri F: Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: role of adenosine and proinflammatory cytokines. / Rheumatology 2002, 41: 1249鈥?260. CrossRef
  29. van Leeuwen MA, Westra J, Limburg PC, van Riel PLCM, van Rijswijk MH: Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid. / Ann Rheum Dis 2002, 54: 33鈥?8. CrossRef
  30. Gabay C: Interleukin-6 and chronic inflammation. / Arthritis Res Ther 2006, 8: 1鈥?. CrossRef
  31. Manshouri T, Quint谩s-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, Cortes JE, Kantarjian HM, Verstovsek S: The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. / Cancer Sci 2008, 99: 1265鈥?273. j.1349-7006.2008.00817.x">CrossRef
  32. Lin TH, Hegen M, Quadros E, Nickerson-Nutter CL, Appell KC, Cole AG, Shao Y, Tam S, Ohlmeyer M, Wang B, Goodwin DG, Kimble EF, Quintero J, Gao M, Symanowicz P, Wrocklage C, Lussier J, Schelling SH, Hewet AG, Xuan D, Krykbaev R, Togias J, Xu X, Harrison R, Mansour T, Collins M, Clark JD, Webb ML, Seidl KJ: Selective functional inhibition of JAK3 kinase is sufficient for efficacy in collagen induced arthritis in mice. / Arthritis Rheum 2010, 62: 2283鈥?293. CrossRef
  33. Haynes DR: Inflammatory cells and bone loss in rheumatoid arthritis. / Arthritis Res Ther 2007, 9: 1鈥?. CrossRef
  34. Niki Y, Yamada H, Seki S, Kikuchi T, Takaishi H, Toyama Y, Fujikawa K, Tada N: Macophage- and neutrophil-dominant arthritis in human IL-1伪 transgenic mice. / J Clin Invest 2001, 107: 1127鈥?135. CrossRef
  35. Parsonage G, Filer A, Bik M, Hardie D, Lax S, Howlett K, Church LD, Raza K, Wong S-H, Trebilcock E, Scheel-Toellner D, Salmon M, Lord JM, Buckley CD: Prolonged, granulocyte-macrophage colony-stimulating factor-dependent, neutrophil survival following rheumatoid synovial fibroblast activation by IL-17 and TNF-alpha. / Arthritis Res Ther 2008, 10: 1鈥?2. CrossRef
  36. Santos LL, Morand EF, Hutchinson P, Boyce NW, Holdsworth SR: Anti-neutrophil monoclonal antibody therapy inhibits the development of adjuvant arthritis. / Clin Exp Immunol 1997, 107: 248鈥?53. j.1365-2249.1997.263-ce1154.x">CrossRef
  37. Katano M, Okamoto K, Arito M, Kawakami Y, Kurokawa MS, Suematsu N, Shimada S, Nakamura H, Xiang Y, Masuko K, Nishioka K, Yudoh K, Kato T: Implication of granulocyte-macrophage colony-stimulating factor induced neutrophil gelatinase-associated lipocalin in pathogenesis of rheumatoid arthritis revealed by proteome analysis. / Arthritis Res Ther 2009, 11: 1鈥?2. CrossRef
  38. Auer J, Blass M, Schulze-Koops H, Russwurm S, Nagel T, Kalden JR, Rollinghoff M, Beuscher HU: Expression and regulation of CCL18 in synovial fluid neutrophils of patients with rheumatoid arthritis. / Arthritis Res Ther 2007, 9: 1鈥?2. CrossRef
  39. Cross A, Barnes T, Bucknall RC, Edwards SW, Moots RJ: Neutrophil apoptosis in rheumatoid arthritis is regulated by local oxygen tensions within joints. / J Leukoc Biol 2006, 80: 521鈥?28. jlb.0306178">CrossRef
  40. Jarvis JN, Petty HR, Tang Y, Frank MB, Tessier PA, Dozmorov I, Jiang K, Kindzelski A, Chen Y, Cadwell C, Turner M, Szodoray P, McGhee JL, Centola M: Evidence for chronic, peripheral activation of neutrophils in polyarticular juvenile rheumatoid arthritis. / Arthritis Res Ther 2006, 8: 1鈥?4. CrossRef
  41. Wipke BT, Allen PM: Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. / J Immunol 2001, 167: 1601鈥?608.
  42. Santos L, Tipping PG: Attenuation of adjuvant arthritis in rats by treatment with oxygen radical scavengers. / Immunol Cell Biol 1994, 72: 406鈥?14. CrossRef
  43. Issekutz AC, Ayer L, Miyasaka M, Issekutz TB: Treatment of established adjuvant arthritis in rats with monoclonal antibody to CD18 and very late activation antigen-4 integrins suppresses neutrophil and T-lymphocyte migration to the joints and improves clinical disease. / Immunology 1996, 88: 569鈥?76. j.1365-2567.1996.d01-695.x">CrossRef
  44. Cedergren J, Forslund T, Sundqvist T, Skogh T: Intracellular oxidative activation in synovial fluid neutrophils from patients with rheumatoid arthritis but not from other arthritis patients. / J Rheumatol 2007, 34: 2162鈥?170.
  45. Hallett MB, Williams AS: Stopping the traffic: A route to arthritis therapy. / Eur J Immunol 2008, 38: 2650鈥?653. ji.200838786">CrossRef
  
• 作者单位：Debra M Meyer (1)
  Michael I Jesson (1)
  Xiong Li (1)
  Mollisa M Elrick (2)
  Christie L Funckes-Shippy (1)
  James D Warner (1)
  Cindy J Gross (2)
  Martin E Dowty (3)
  Shashi K Ramaiah (2)
  Jeffrey L Hirsch (1)
  Matthew J Saabye (1)
  Jennifer L Barks (1)
  Nandini Kishore (1)
  Dale L Morris (2)
  
  1. Worldwide Research, Pfizer Global Research & Development, Chesterfield, MO, USA
  2. Drug Safety R&D, Pfizer Global Research & Development, Chesterfield, MO, USA
  3. Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research & Development, Chesterfield, MO, USA
  
• ISSN：1476-9255

文摘

Background The Janus kinase (JAK) family of tyrosine kinases includes JAK1, JAK2, JAK3 and TYK2, and is required for signaling through Type I and Type II cytokine receptors. CP-690,550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications. In RA trials, dose-dependent decreases in neutrophil counts (PBNC) were observed with CP-690,550 treatment. These studies were undertaken to better understand the relationship between JAK selectivity and PBNC decreases observed with CP-690,550 treatment. Methods Potency and selectivity of CP-690,550 for mouse, rat and human JAKs was evaluated in a panel of in vitro assays. The effect of CP-690,550 on granulopoiesis from progenitor cells was also assessed in vitro using colony forming assays. In vivo the potency of orally administered CP-690,550 on arthritis (paw edema), plasma cytokines, PBNC and bone marrow differentials were evaluated in the rat adjuvant-induced arthritis (AIA) model. Results CP-690,550 potently inhibited signaling through JAK1 and JAK3 with 5-100 fold selectivity over JAK2 in cellular assays, despite inhibiting all four JAK isoforms with nM potency in in vitro enzyme assays. Dose-dependent inhibition of paw edema was observed in vivo with CP-690,550 treatment. Plasma cytokines (IL-6 and IL-17), PBNC, and bone marrow myeloid progenitor cells were elevated in the context of AIA disease. At efficacious exposures, CP-690,550 returned all of these parameters to pre-disease levels. The plasma concentration of CP-690,550 at efficacious doses was above the in vitro whole blood IC50 of JAK1 and JAK3 inhibition, but not that of JAK2. Conclusion Results from this investigation suggest that CP-690,550 is a potent inhibitor of JAK1 and JAK3 with potentially reduced cellular potency for JAK2. In rat AIA, as in the case of human RA, PBNC were decreased at efficacious exposures of CP-690,550. Inflammatory end points were similarly reduced, as judged by attenuation of paw edema and cytokines IL-6 and IL-17. Plasma concentration at these exposures was consistent with inhibition of JAK1 and JAK3 but not JAK2. Decreases in PBNC following CP-690,550 treatment may thus be related to attenuation of inflammation and are likely not due to suppression of granulopoiesis through JAK2 inhibition.